Abdellah Samira Ait, Berlin Aurélie, Blondeau Claude, Guinobert Isabelle, Guilbot Angèle, Beck Marc, Duforez François
Groupe PiLeJe, 37 quai de Grenelle, 75015, Paris Cedex 15, France.
1 avenue Cornaudric, 31240, L'Union, France.
J Tradit Complement Med. 2019 Mar 1;10(2):116-123. doi: 10.1016/j.jtcme.2019.02.003. eCollection 2020 Mar.
Cham. and L. have long been used for the management of sleep disorders and anxiety. Use of a fixed combination of these two plant extracts (Phytostandard® d'Eschscholtzia et de Valériane, PiLeJe Laboratoire, France) was investigated in an observational study. Adults with adjustment insomnia according to the criteria of the International Classification of Sleep Disorders and with an insomnia severity index (ISI) score >7 enrolled by GPs took a maximum of four tablets of the eschscholtzia and valerian combination every night for four weeks. Within one month, ISI score decreased by approximately 30% (from 16.09 ± 3.67 at inclusion (V1) to 11.32 ± 4.78 at 4 weeks (V2); p < 0.0001). Night sleep duration significantly increased between the first and the fourth week of supplement intake, sleep efficiency increasing from 78.4% ± 12.5 to 84.6% ± 10.2 (p = 0.002). There was no improvement in sleep latency. The number of awakenings decreased by approximately 25% and their total duration by approximately 25 min. Anxiety score significantly decreased by 50% from 13.9 ± 7.3 at V1 to 6.7 ± 6.3 at V2 (p < 0.0001). The supplement was well tolerated. These results suggest that the tested combination of eschscholtzia and valerian extracts could be beneficial for the management of insomnia in adults and deserves further investigation.
延胡索和缬草长期以来一直用于治疗睡眠障碍和焦虑症。在一项观察性研究中,对这两种植物提取物的固定组合(Phytostandard® d'Eschscholtzia et de Valériane,法国PiLeJe实验室)的使用情况进行了调查。根据国际睡眠障碍分类标准诊断为适应性失眠且失眠严重程度指数(ISI)评分>7的成年人,由全科医生招募,每晚最多服用四片延胡索和缬草组合制剂,持续四周。在一个月内,ISI评分下降了约30%(从纳入时(V1)的16.09±3.67降至4周时(V2)的11.32±4.78;p<0.0001)。补充剂摄入的第一周和第四周之间,夜间睡眠时间显著增加,睡眠效率从78.4%±12.5提高到84.6%±10.2(p=0.002)。睡眠潜伏期没有改善。觉醒次数减少了约25%,其总时长减少了约25分钟。焦虑评分从V1时的13.9±7.3显著下降了50%,至V2时的6.7±6.3(p<0.0001)。该补充剂耐受性良好。这些结果表明,所测试的延胡索和缬草提取物组合可能对成人失眠的治疗有益,值得进一步研究。